Loading patent…
AssigneeBiosynexus Incorporated
InventorsRichard F. Schuman, John Fitzgerald Kokai-Kun, Simon J. Foster, Jeffrey R. Stinson, Gerald Walter Fischer
Estimating the term…
The present invention encompasses protective monoclonal antibodies that bind to peptidoglycan of Gram-positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and block nasal colonization by Gram-positive bacteria in vivo. The invention also provides human, humanized and chimeric antibodies. The invention also sets forth the heavy chain and light chain variable regions of an antibody within the invention.
A method for treating a patient comprising, administering a therapeutically effective amount of a composition comprising at least one MAb that binds to peptidoglycan (PepG) of Gram-positive bacteria;
A composition comprising, a therapeutically effective amount of at least one MAb that binds to peptidoglycan (PepG) of Gram-positive bacteria;
A hybridoma cell line deposited at the ATCC under accession no. PTA-2492.
A hybridoma cell line deposited at the ATCC under accession no. PTA-3659.
A vaccine comprising at least one purified PepG, peptides, fragments and epitopes therof, in a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.